References:
1. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed
intensification improves event-free survival for children with
intermediate-risk acute lymphoblastic leukemia: a report from the
Children’s Cancer Group. Blood. 2002;99(3):825-833.
2. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus
prednisone and daily oral versus weekly intravenous mercaptopurine for
patients with standard-risk acute lymphoblastic leukemia: a report from
the Children’s Cancer Group. Blood. 2003;101(10):3809-3817.
3. Hutchinson RJ, Gaynon PS, Sather H, et al. Intensification of therapy
for children with lower-risk acute lymphoblastic leukemia: long-term
follow-up of patients treated on Children’s Cancer Group Trial 1881.J Clin Oncol. 2003;21(9):1790-1797.
4. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia.Lancet Oncol. 2013;14(6):e205-217.
5. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the
children’s cancer group studies for childhood acute lymphoblastic
leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia.2010;24(2):285-297.
6. Krishnan S, Wade R, Moorman AV, et al. Temporal changes in the
incidence and pattern of central nervous system relapses in children
with acute lymphoblastic leukaemia treated on four consecutive Medical
Research Council trials, 1985-2001. Leukemia. 2010;24(2):450-459.
7. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber
Cancer Institute Consortium protocols for children with newly diagnosed
acute lymphoblastic leukemia (1981-1995). Leukemia.2000;14(12):2247-2256.
8. Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine
during interval therapy of a Berlin-Frankfurt-Munster-based protocol in
increased-risk children with acute lymphoblastic leukemia and
lymphoblastic lymphoma: results of the European Organization for
Research and Treatment of Cancer 58881 randomized phase III trial.J Clin Oncol. 2001;19(7):1935-1942.
9. Pui CH, Campana D, Pei D, et al. Treating childhood acute
lymphoblastic leukemia without cranial irradiation. N Engl J Med.2009;360(26):2730-2741.
10. Yeh TC, Liang DC, Hou JY, et al. Treatment of childhood acute
lymphoblastic leukemia with delayed first intrathecal therapy and
omission of prophylactic cranial irradiation: Results of the
TPOG-ALL-2002 study. Cancer. 2018;124(23):4538-4547.
11. Jeha S, Pei D, Choi J, et al. Improved CNS Control of Childhood
Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total
Therapy Study 16. J Clin Oncol. 2019;37(35):3377-3391.
12. Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008
treatment for patients aged 1-45 years with acute lymphoblastic
leukemia. Leukemia. 2018;32(3):606-615.
13. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in Late Mortality
among 5-Year Survivors of Childhood Cancer. N Engl J Med.2016;374(9):833-842.
14. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based
therapy for childhood acute lymphoblastic leukaemia: results of the
prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9
(1997-2004). Lancet Oncol. 2009;10(10):957-966.
15. Larsen EC, Devidas M, Chen S, et al. Dexamethasone and High-Dose
Methotrexate Improve Outcome for Children and Young Adults With
High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s
Oncology Group Study AALL0232. J Clin Oncol.2016;34(20):2380-2388.
16. Moricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs
prednisone in induction treatment of pediatric ALL: results of the
randomized trial AIEOP-BFM ALL 2000. Blood.2016;127(17):2101-2112.
17. Maloney KW, Devidas M, Wang C, et al. Outcome in Children With
Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s
Oncology Group Trial AALL0331. J Clin Oncol. 2020;38(6):602-612.
18. Attarbaschi A, Mann G, Zimmermann M, et al. Randomized
post-induction and delayed intensification therapy in high-risk
pediatric acute lymphoblastic leukemia: long-term results of the
international AIEOP-BFM ALL 2000 trial. Leukemia.2020;34(6):1694-1700.
19. Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Barredo J, Buchanan
GR. Improved survival of children with isolated CNS relapse of acute
lymphoblastic leukemia: a pediatric oncology group study. J Clin
Oncol. 1999;17(12):3745-3752.
20. Barredo JC, Devidas M, Lauer SJ, et al. Isolated CNS relapse of
acute lymphoblastic leukemia treated with intensive systemic
chemotherapy and delayed CNS radiation: a pediatric oncology group
study. J Clin Oncol. 2006;24(19):3142-3149.
21. Richards S, Pui CH, Gayon P, Childhood Acute Lymphoblastic Leukemia
Collaborative G. Systematic review and meta-analysis of randomized
trials of central nervous system directed therapy for childhood acute
lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(2):185-195.
22. Sirvent N, Suciu S, Rialland X, et al. Prognostic significance of
the initial cerebro-spinal fluid (CSF) involvement of children with
acute lymphoblastic leukaemia (ALL) treated without cranial irradiation:
results of European Organization for Research and Treatment of Cancer
(EORTC) Children Leukemia Group study 58881. Eur J Cancer.2011;47(2):239-247.
23. Liu HC, Yeh TC, Hou JY, et al. Triple intrathecal therapy alone with
omission of cranial radiation in children with acute lymphoblastic
leukemia. J Clin Oncol. 2014;32(17):1825-1829.
24. Vora A, Andreano A, Pui CH, et al. Influence of Cranial Radiotherapy
on Outcome in Children With Acute Lymphoblastic Leukemia Treated With
Contemporary Therapy. J Clin Oncol. 2016;34(9):919-926.
25. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of
secondary neoplasms as a first event after childhood acute lymphoblastic
leukemia. JAMA. 2007;297(11):1207-1215.
26. Pui CH, Howard SC. Current management and challenges of malignant
disease in the CNS in paediatric leukaemia. Lancet Oncol.2008;9(3):257-268.
27. Hill FG, Richards S, Gibson B, et al. Successful treatment without
cranial radiotherapy of children receiving intensified chemotherapy for
acute lymphoblastic leukaemia: results of the risk-stratified randomized
central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).Br J Haematol. 2004;124(1):33-46.
28. Goldsby RE, Liu Q, Nathan PC, et al. Late-occurring neurologic
sequelae in adult survivors of childhood acute lymphoblastic leukemia: a
report from the Childhood Cancer Survivor Study. J Clin Oncol.2010;28(2):324-331.
29. Kunin-Batson A, Kadan-Lottick N, Neglia JP. The contribution of
neurocognitive functioning to quality of life after childhood acute
lymphoblastic leukemia. Psychooncology. 2014;23(6):692-699.
30. Mulrooney DA, Hyun G, Ness KK, et al. The changing burden of
long-term health outcomes in survivors of childhood acute lymphoblastic
leukaemia: a retrospective analysis of the St Jude Lifetime Cohort
Study. Lancet Haematol. 2019;6(6):e306-e316.
31. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among
survivors of childhood acute lymphoblastic leukemia: a report from the
Childhood Cancer Survivor Study. Blood. 2008;111(12):5515-5523.
32. Follin C, Erfurth EM. Long-Term Effect of Cranial Radiotherapy on
Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia
Survivors. Curr Treat Options Oncol. 2016;17(9):50.
33. Shimazaki S, Kazukawa I, Mori K, Kihara M, Minagawa M. Factors
predicting endocrine late effects in childhood cancer survivors from a
Japanese hospital. Endocr J. 2020;67(2):131-140.
34. Ribeiro RC, Rivera GK, Hudson M, et al. An intensive re-treatment
protocol for children with an isolated CNS relapse of acute
lymphoblastic leukemia. J Clin Oncol. 1995;13(2):333-338.
35. Smith M, Bleyer A, Crist W, Murphy S, Sallan SE. Uniform criteria
for childhood acute lymphoblastic leukemia risk classification. J
Clin Oncol. 1996;14(2):680-681.
36. Barredo JC, Hastings C, Lu X, et al. Isolated late testicular
relapse of B-cell acute lymphoblastic leukemia treated with intensive
systemic chemotherapy and response-based testicular radiation: A
Children’s Oncology Group study. Pediatr Blood Cancer.2018;65(5):e26928.
37. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of
minimal residual disease in high risk B-ALL: a report from Children’s
Oncology Group study AALL0232. Blood. 2015;126(8):964-971.
38. Kaplan E, Meier P. Nonparametric estimation from incomplete
observations. Journal of the American Statistical Society.1958;53:457-481.
39. Peto R, Pike MC, Armitage P, et al. Design and analysis of
randomized clinical trials requiring prolonged observation of each
patient. II. analysis and examples. Br J Cancer. 1977;35(1):1-39.
40. Frishman-Levy L, Shemesh A, Bar-Sinai A, et al. Central nervous
system acute lymphoblastic leukemia: role of natural killer cells.Blood. 2015;125(22):3420-3431.
41. Gu R, Liu F, Zou D, et al. Efficacy and safety of CD19 CAR T
constructed with a new anti-CD19 chimeric antigen receptor in relapsed
or refractory acute lymphoblastic leukemia. J Hematol Oncol.2020;13(1):122.
42. He X, Xiao X, Li Q, et al. Anti-CD19 CAR-T as a feasible and safe
treatment against central nervous system leukemia after intrathecal
chemotherapy in adults with relapsed or refractory B-ALL.Leukemia. 2019;33(8):2102-2104.
43. Jacoby E, Bielorai B, Avigdor A, et al. Locally produced CD19 CAR T
cells leading to clinical remissions in medullary and extramedullary
relapsed acute lymphoblastic leukemia. Am J Hematol.2018;93(12):1485-1492.
44. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in
Children and Young Adults with B-Cell Lymphoblastic Leukemia. N
Engl J Med. 2018;378(5):439-448.
45. Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades
after treatment for childhood acute lymphoblastic leukemia: a report
from the St Jude lifetime cohort study. J Clin Oncol.2013;31(35):4407-4415.
46. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms
subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic
leukemia in childhood: significantly lower risk without cranial
radiotherapy. Blood. 2000;95(9):2770-2775.
47. Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in
adult survivors of childhood cancers treated with cranial radiotherapy:
a report from the St Jude Lifetime Cohort study. J Clin Oncol.2015;33(5):492-500.